tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
PremiumRatingsStrategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
1M ago
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Premium
Company Announcements
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
2M ago
Foghorn Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Foghorn Therapeutics initiated with a Buy at Guggenheim
2M ago
Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
PremiumRatingsFoghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating
2M ago
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating
2M ago
Foghorn Therapeutics Announces Key Pipeline Updates
Premium
Company Announcements
Foghorn Therapeutics Announces Key Pipeline Updates
2M ago
Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
PremiumRatingsBuy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers
5M ago
Foghorn Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Foghorn Therapeutics Reports Q2 2025 Financial Results
5M ago
Foghorn Therapeutics management to meet virtually with B. Riley
Premium
The Fly
Foghorn Therapeutics management to meet virtually with B. Riley
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100